Javelin Pharmaceuticals Inc (JAV)

[apljack]

I came away from reading the transcript with a similar impression. Gotta believe, however, that the co's interested know that they have JAV behind the 8-ball, at least at this point. The share price has been awful, and the cash burn will weigh heavily on JAV's bargain position.

On the up side, the adoption of Dyloject has gone better than expected at both the formulary end and use end. We can also expect that the top line results will cement opinion about Dyloject's value in the US.

I can't do much moe buying right now, but I'm sure not gonna sell.

aj